July 14, 2004
Novartis' new research home in a former candy factory is but one ingredient in a new recipe for success that embraces leadership, culture, science, and technology.
By Kevin Davies and John Russell
Metabolomics is attracting a flurry of biotechs and academics, with research implications ranging from plant biology to drug discovery.
By Karen HopkinHorizonsConversation: Stephen Fodor
Affymetrix CEO Stephen Fodor discusses building a tech business without a blueprint.Innovation
Software solutions provide context for a pathways approach to genomic data analysis.Guest Commentary
Abiding by information security rules is essential to doing business internationally.Departments News & Analysis IBM’s Super DuoDIA: Users Want Tools That WorkOncologists Wrestle with Drug MechanismsLife Science Real Estate ReportGenzyme’s Big Oncology BetCancer Center Adds SGI to the MixUS Genomics Launches First ProductSynthetic Biology: The Real ThingAccelrys Reborn as …. Accelrys Columns First Base
| Kevin Davies
What is the truth behind the cost of new drugs?Inside the Box
| Bill van Etten
R is rapidly gaining acceptance in bioinformatics.Fully Equipped
| Julia Boguslavsky
ASMS showcases mass spec and proteomics.The Russell Transcript
| John Russell
San Diego boasts sun, surf, and a biotech hotbed.